Deciphera Pharmaceuticals Inc Stock News

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward tre

The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve

Deciphera Pharmaceuticals has seen a 50% upside with successful phase 3 trial results. DCPH has achieved positive data in a subpopulation of patients with KIT exon 11 primary mutation. The company's p

Deciphera Pharmaceuticals continues to make progress with its flagship drug ripretinib, with positive phase 3 results and ongoing trials. They are also working on commercializing the CSF1R inhibitor v

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve

Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.55 per share a year ago.

Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. The INSIGHT study is comparing ripretinib against

Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.

Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a part of a combination therapy.

Deciphera saw revenue rise by 17.4% year over year. The company's only marketed therapy is Qinlock to treat advanced GIST.

Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.